JAMA Network
About The Study: Global early-stage drug development has nearly doubled over the past decade, shifting from a system dominated by the U.S. toward a 2-hub structure centered on the U.S. and China. Because early-stage drug candidates shape future drug approvals and investment, these shifts may have downstream implications for regulatory coordination, scientific workforce development, and patient access to new therapies. Continued monitoring will be essential for policymakers to understand these consequences and to design appropriate financial and regulatory incentives.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
